Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ Научный центр психического здоровья РАМН Минздрава РФ, Москва
Список исп. литературыСкрыть список 1. Андрющенко А.В., Бескова Д.А. Терапевтические аспекты применения Феварина по результатам натуралистической программы MODuS. Психиатр. и психофармакотер. 2008; 10 (6): 8–13. 2. Вертоградова О.П. Тревожно-фобические расстройства и депрессия. В кн.: Тревога и обсессии. Под ред. А.Б.Смулевича. М.: НЦПЗ РАМН, 1998; с. 113–31. 3. Вовин Р.Я., Аксенова И.О. Затяжные депрессивные состояния. Л.: Медицина, 1982. 4. Ганнушкин П.Б., Суханов С.А. О циркулярном психозе и циркулярном течении. Мед. обозрение. 1903; 59 (1): 3–14. 5. Дмитриева Т.Б., Краснов В.Н., Незнанов Н.Г. и др. Психиатрия: национальное руководство. М.: ГЭОТАР-Медиа, 2009. 6. Каннабих Ю.В. Циклотимия, ее симптоматология и течение. М., 1914. 7. Кинкулькина М.А. Лечение тяжелых эндогенных депрессий Феварином (флувоксамин). Психиатр. и психофармакотер. 2007; 9 (4): 39–44. 8. Краснов В.Н. Расстройства аффективного спектра. М.: Практич. медицина, 2011. 9. Личко А.Е. Психопатии и акцентуации характера у подростков. Л.: Медицина, 1983. 10. Марилов В.В. Общая психопатология. М.: Академия, 2002. 11. Матюшенко Е.Н. Применение флувоксамина (Феварина) в общей медицине (обзор литературы). Психич. расстройства в общей медицине. Под ред. А.Б.Смулевича. 2011; 3–4: 52–5. 12. Нуллер Ю.Л., Михаленко И.Н. Аффективные психозы. Л.: Медицина, 1988. 13. Самушия М.А. Феварин (флувоксамин) в терапии тревожно-депрессивных нозогенных реакций у пациентов с онкологическими заболеваниями. Психич. расстройства в общей медицине. Под ред. А.Б.Смулевича. 2008; 1: 33–7. 14. Суханов С.А. Семиотика и диагностика душевных болезней. 1905; 2: 109–24. 15. Суханов С.А. Циклотимия и психастения и их отношение к неврастении. Рус. врач. 1903; 3: 79–81. 16. Фотьянов М.И. О затяжном течении инволюционной меланхолии. Журн. невропатол. и психиатр. им. С.С.Корсакова. 1965; 65 (4): 575–83. 17. Штернберг Э.Я., Рохлина М.Л. О некоторых клинических особенностях депрессий позднего возраста. В кн.: Депрессии: вопросы клиники, психопатологии, терапии. Под ред. Э.Я.Штернберга, А.Б.Смулевича. Доклады симпозиума 10–12 сентября 1970 г. М.: Базель, 1970. 18. Ajmo CT, Vernon DO, Collier L et al. Sigma-receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats. Curr Neurovas Res 2006; 3 (2): 89–98. 19. Andreasen NC, Carpenter WT, Cane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiat 2005; 162 (3): 441–9. 20. Baldwin RC, Gallagley A, Gourlay M et al. Prognosis of late life depression: a 3-year cohort study of outcome and potential predictors. Int J Geriatr Psychiat 2006; 21 (1): 57–63. 21. Barnhofer T, Chittka T. Cognitive reactivity mediates the relationship between neuroticism and depression. Behav Res Therap 2010; 48 (4): 275–81. 22. Beck AT, Rush AJ, Shaw BF et al. Cognitive therapy of depression. NY: Guilford Press, 1979. 23. Bonnet H. Les formes atypiques d\'excitation der l\'humeur ou les excitations et les manies Masquees. Lyon med 1979; 241 (1): 25–34. 24. Boyce Ph, Parker G, Hickie I et al. Personality differences between patients with remitted melancholic and nonmelancholic depression. Am J Psychiat 1990; 147 (11): 1476–83. 25. Calanca et al. Vade-Mecum de therapeutique psychiatriqe. Geneve: editions medecine et hygiene, 1997. 26. Concise color medical dictionary. 5th ed. Ed. A.Elizabeth UK: Oxford University Press, 2010. 27. Conway M, Csank PA, Holm SL et al. On assessing individual differences in rumination on sadness. J Person Assessment 2000; 75: 404–25. 28. Danion J-M, Kauffmann-Muller FA. Депрессия и память. Медикография. 1994; 16 (56): 21–8. 29. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12 (3): 189–98. 30. Gross JJ, Sutton SK, Ketelaar T. Relations between affect and personality: support for the affect-level and affective-reactivity views. Person and Soc Psychol Bull 1998; 24: 279–88. 31. Hamilton M. Development of a rating scale for primary depressive illness. Br J Social Clin Psychol 1967; 6: 278–96. 32. Hashimoto K, Ishiwata K. Sigma-receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr Pharm Des 2006; 12: 3857–76. 33. Hayashi T, Su TP. The potential role of sigma-1 receptors in lipid transport and lipid raft reconstitution in the brain: implication for drug abuse. Life Sci 2005; 77 (14): 1612–24. 34. Helmchen H, Linden M. Subthreshold disorders in psychiatry: clinical reality, methodological artifact, and the double-threshold problem. Comp Psychiat 2000; 41: 1–7. 35. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Intern J Clin Practice 2009; 63 (7): 1085–94. 36. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconcidered. Hum Psychopharmacol Clin Exp 2010; 25: 193–200. 37. Ishikawa M, Ishiwata K, Ishii K et al. High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using SA4503. Biol Psychiat 2007; 62: 878–83. 38. Jhingan HP, Sagar R, Pandey RM. Prognosis of late-onset depression in the elderly: a study from India. Int Psychogeriat 2001; 13 (1): 51–61. 39. Johnson MH, Magaro PA. Effects of mood and severity on memory processes in depression and mania. Psychol Bull 1987; 101 (1): 28–40. 40. Katoh Y, Uchida S, Kawai M et al. Onset of clinical effects and plasma concentration of fluvoxamine in Japanese patients. Biol Pharm Bull 2010; 33 (12): 1999–2002. 41. Kielholz P. Chronishce endogene Depressionen. Chronische endogene Psychosen. Hrsg. H. von Kranz, K.Heinrich. Stutgart, 1973; s5–7. 42. Koran LM, Bromberg D, Hornfeldt CS et al. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Comp Psychiat 2010; 51 (4): 373–9. 43. Leonhard K. Aufleitung der endogenen psychosen. Berlin: Akademie-Verlag, 1957. 44. Li Z, Cui S, Zhang Z et al. DHEA-neuroprotection and neurotoxicity after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2009; 29 (2): 287–96. 45. Mandelli L, Seretti A, Colombo C et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiat Clin Neuroscienc 2006; 60: 598–604. 46. Maurice T. Neitrosteroids and sigma-1 receptors, biochemical and behavioral relevance. Pharmacopsychiat 2004; 37: 171–82. 47. Nolen-Hoeksema S. Responses to depression and their effects on the duration of depressive episodes. J Abnorm Psychol 1991; 100: 569–82. 48. Nutt D, Rickels K, Stein DJ. Generalized anxiety disorders. Symptomatology, pathogenesis and management. Lond Martin Dunitz, 2002. 49. Rippere V. What’s the thing to do when you are feeling depressed? A pilot study. Behav Res and Ther 1977; 15: 185–91. 50. Rossini D, Serretti A, Franchini L, Mandelli L et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol 2005; 25: 471–5. 51. Shimoda M. Űber das manisch-depressive Irresein. Med Zischr Yonago 1950; 2: 1–2. 52. Shinfuku N, Ihda S. Űeber den praemorbiden Charakter der endogenen Depression – Immodithymie (spaeter Immobilithymie) von Shimoda. Fortschritte der Neurologie, Psychiatrie und ihrer Grenzgebite 1969; 10: 546–52. 53. Stahl SM. Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 2005; 10 (4): 319–23. 54. Stein DJ, Hollander E. Textbook of anxiety disorders. Washington. Am Psychiat Publish, 2002. 55. Tellenbach H. Melancholy: history of the problem. Endogeneity, typology, pathogenesis, clinical considerations. Pittsburgh, PA: Duquesne University Press, 1961. 56. Tölle R. Katamnestische unterysuchungen zur biographie abnormer persönlichkeiten. 115 Katamnesen 22–37 Jahre nach klinischer Behandlung, 1966. 57. Troy AS, Mauss IB. Resilience the face of stress: emotion regulation as a protective factor. Resilience and mental health: challenges across the lifespan. Ed. S.Southwick, B.Litz, D.Charney et al. Cambridge University Press, 2011; p. 30–44. 58. Tyrer P. The case for cothymia: mixed anxiety and depression as a single diagnosis. Br J Psych 2001; 179: 191–3. 59. Vieta E, Colom F, Corbella B et al. Clinical correlates of psychiatric comorbidity in bipolar I patients. Bipolar Disord 2008; 3 (5): 253–8. 60. Wells A, Matthews G. Attention and emotion: a clinical perspective. Hove, UK. Lawrence Erlbaum, 1994. 61. Wells A, Matthews G. Modeling cognition therapy in emotional disorders: the S-REF model. Behav Res and Ther 1996; 34: 881–8. 62. Wittchen HU, Beesdoa K, Bittnera A et al. Depressive episodes – evidence for casual role of primary anxiety disorders? Eur Psychiat 2003; 18: 384–93.